Summary
Pfizer Inc. filed this Form 8-K on April 28, 2015, primarily to furnish a press release announcing its financial results for the first quarter of 2015. While the 8-K itself contains minimal detail, it directs investors to the attached press release (Exhibit 99) for comprehensive information regarding the company's performance during the period. Investors should review this press release for specific revenue, earnings, and operational updates from Pfizer.
Key Highlights
- 1Pfizer announced its first-quarter 2015 financial results on April 28, 2015.
- 2The 8-K filing serves as a mechanism to incorporate the press release containing these results.
- 3The press release, filed as Exhibit 99, is the primary source of detailed financial and operational information.
- 4Investors are directed to the press release for specific performance metrics.
- 5The filing confirms that the press release is considered 'filed' under the Securities Exchange Act of 1934.
Frequently Asked Questions
The main purpose of this 8-K filing is to officially submit Pfizer's press release announcing its first-quarter 2015 financial results to the SEC. It effectively makes the press release part of the company's official regulatory filings.
The detailed financial results for Pfizer's first quarter of 2015 are located in the press release filed as Exhibit 99 to this 8-K filing. You will need to access that press release for specific numbers and commentary.
No, this specific 8-K filing does not contain the actual financial figures itself. It only announces that Pfizer has released its Q1 2015 results and incorporates the press release by reference, which holds the detailed financial information.